RCT: Celecoxib for 3 years added to standard adjuvant therapy does not improve disease-free survival among patients with stage III colon cancer
7 Apr, 2021 | 01:28h | UTCEffect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Celecoxib for Stage III Colon Cancer – JAMA (free for a limited period)